Iptacopan · Fabhalta
Small molecule
Also known as LNP023
Evidence outlook
Approved: Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy, Complement-Mediated Renal Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Chronic Kidney Disease · Phase 3Age-Related Macular Degeneration · Phase 2Generalized Myasthenia Gravis · Phase 3
Also approved (5)
- Complement 3 Glomerulopathy FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
- Adult patients with complement 3 glomerulopathy (C3G)
- Monotherapy in adult patients with paroxysmal nocturnal haemoglobinuria (PNH)
- Paroxysmal nocturnal haemoglobinuria (PNH), adults; Japanese brand name written Fabihalta in katakana; date from the Novartis Japan release of 2024-06-24
- Adult PNH patients who have not previously received complement inhibitor therapy (NMPA notice updated 2024-04-30)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04558918 NCT04558918 · Paroxysmal Nocturnal Hemoglobinuria This randomized trial compared iptacopan with continued standard anti-C5 antibody therapy and met both main measures by a wide margin, and those measures are based on hemoglobin, a laboratory value. Patients and doctors knew which treatment was given and the trial was modest in size (97 patients), so the design falls short of the highest grade. Registry: NCT04558918 | 3 | Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions; Marginal Proportion (Expressed as Percentages) of Participants With Sustained Hemoglobin Levels of ≥ 12 g/dL in the Absence of Red Blood Cell Transfusions 2022-09-26 | At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. | Partial signal | link ↗ |
View 1 more trial
APPOINT-PNH NCT04820530 · Paroxysmal Nocturnal Hemoglobinuria The study was an open-label, single-arm trial of 40 participants receiving iptacopan, without randomization or a placebo/active comparator. Although the clinical primary endpoint was reported as 92.2% responders, the uncontrolled design cannot establish how much of the result was due to iptacopan. Registry: NCT04820530 | 3 | Marginal Proportion (Expressed as Percentage) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions 2022-11-02 | Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other Complement Factor B drugs
HRS-5965, FWY003, ALN-CFB. Compare all 4 Complement Factor B drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Age-Related Macular Degeneration: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Iptacopan (Fabhalta): this drug | Phase 2 | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal | NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42% | |
| Aflibercept-Abzv (Enzeevu) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved | Protein / enzyme therapeutic | VEGF-A | Reliable signal | NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) | |
| Aflibercept-Boav (Eydenzelt) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Avacincaptad Pegol (Izervay) | Approved | RNA Aptamer | Complement C5 | Reliable signal | NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165). NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072) | |
| Brolucizumab-Dbll | Approved | Antibody fragment | VEGF-A | Weak signal | No reviewed efficacy summary in this indication | |
| Faricimab | Approved | Multispecific antibody | Angiopoietin-2 / VEGF-A | Partial signal | NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results). NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results). | |
| Pegcetacoplan Ophthalmic (Syfovre) | Approved | Peptide | Complement C3, Complement C3 / C3b | Reliable signal | NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218) NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed | |
| Ranibizumab (Lucentis) | Approved | Antibody fragment | VEGF-A | Partial signal | NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham. | |
| Ranibizumab-Eqrn (Cimerli) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Nuna (Byooviz) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Verteporfin (Visudyne) | Approved | Small molecule | Benzoporphyrin-derivative photosensitizer for photodynamic therapy | Partial signal | NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed | |
| Axitinib Intravitreal Implant (OTX-TKI) | Phase 3 | Small molecule | VEGF receptors + PDGF receptors | Partial signal | NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17). | |
| BAT5906 | Phase 3 | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-701 (Lucenbies) | Phase 3 | Monoclonal antibody | VEGF-A | Reliable signal | NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). | |
| HLX04-O | Phase 3 | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ximluci) | Phase 3 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| RC28-E | Phase 3 | Protein / enzyme therapeutic | VEGF-A / FGF-2 (dual blockade) | Partial signal | NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg) | |
| Surabgene Lomparvovec | Phase 3 | Gene therapy / editing | VEGF-A | Weak signal | NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 | |
| Tabirafusp Tedromer | Phase 3 | Multispecific antibody | VEGF + IL-6 | Partial signal | NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28). | |
| Tarcocimab Tedromer | Phase 3 | Monoclonal antibody | VEGF-A | Partial signal | NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28). | |
| Vonaprument | Phase 3 | Antibody fragment | Complement C1q | Partial signal | NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed | |
| MW02 | Phase 2/3 | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| BI 1584862 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| BI 771716 | Phase 2 | Antibody fragment | — | Weak signal | Featured results are safety only in this race | |
| FWY003 | Phase 2(overall) | Undisclosed | Complement Factor B | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-6628 | Phase 1/2 | Antibody fragment | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| SAR402663 | Phase 1/2 | Gene therapy / editing | VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| SAR446597 | Phase 1/2 | Gene therapy / editing | Complement C1s + Factor Bb | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rimmyrah) | Phase 1 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Lazucirnon | Discontinued | Small molecule | CCR3 | Partial signal | NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results). |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fabhalta (Iptacopan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
January 2027 (1)
April 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
2030 (2)
2031 (1)
October 2031 (1)
What to watch
2032 (1)
July 2032 (1)
What to watch
2036 (1)
May 2036 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent